Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | F10 | P00742 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659227 | 0.94 | NPSR1 (0.48) | NPSR1LMNAMEN1KMT2AF10 | |
| SCHEMBL3833308 | 0.90 | NPSR1 (0.59) | NPSR1LMNAMEN1KMT2AF10 | |
| SCHEMBL3830280 | 0.90 | F10 (0.59) | NPSR1LMNAMEN1KMT2AF10 | |
| SCHEMBL3830720 | 0.88 | LMNA (0.52) | NPSR1LMNAMEN1KMT2AF10 | |
| SCHEMBL3832564 | 0.86 | NPSR1 (0.54) | NPSR1LMNAMEN1KMT2AF10 | |
| SCHEMBL3831783 | 0.86 | NPC1 (0.64) | NPSR1LMNAMEN1KMT2AF10 | |
| SCHEMBL6598342 | 0.84 | F10 (0.53) | NPSR1LMNAMEN1KMT2AF10 | |
| SCHEMBL3828873 | 0.84 | F10 (0.71) | F10ALDH1A1L3MBTL1 | |
| SCHEMBL29640020 | 0.81 | ALDH1A1 (0.70) | NPSR1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2198809 | 0.81 | KMT2A (0.68) | NPSR1LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | PFIZER INC | 2009-09-03 | — | — | US | disclosed |
| EP-2085391-A2 | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade | Warner-Lambert Company LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | WARNER-LAMBERT COMPANY LLC | 2008-11-20 | — | — | US | disclosed |
| US-7407974-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407972-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1671949-B1 | Substituted Pyridinylamines | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-11-10 | — | — | US | disclosed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | TFPI, F11, F2 | NPSR1 1749/4885LMNA 329/4885MEN1 1007/4885 |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | NPSR1 1351/4885LMNA 389/4885MEN1 880/4885 |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, F11, F12 | NPSR1 1601/4885LMNA 562/4885MEN1 726/4885 |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | NPSR1 1712/4885LMNA 412/4885MEN1 842/4885 |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | NPSR1 706/4885LMNA 349/4885MEN1 990/4885 |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | NPSR1 1712/4885LMNA 412/4885MEN1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.